A
Atara Biotherapeutics, Inc. (ATRA)
NMS – Real Time Price. Currency in USD
10.51
+0.29 (2.84%)
At close: Jun 26, 2026, 4:00 PM EDT
10.51
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
10.51
+0.29 (2.84%)
At close: Jun 26, 2026, 4:00 PM EDT
10.51
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
No Data
There are no news for this stock.
Total debt $51.6M significantly exceeds cash reserves ($8.4M), raising financial stability concerns
Total current assets $12.2M exceed Total current liabilities $5.6M, highlighting excellent liquidity
Debt-to-equity ratio (-1.4) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-4.1x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$3.1M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.16 | 6.05 | 10 | |
| Quick ratio | 2.16 | 5.63 | 10 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 2.58 | 1.04 | 1.0 | |
| Interest coverage | -4.06 | -16.91 | 1.0 | |
| Weighted average score | 4.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 64M | 9M | 129M | 121M | 23M |
| Gross Profit | 49M | -313K | 108M | 100M | 22M |
| Operating Income | -275M | -269M | -78M | 50M | -6M |
| Net Income | -228M | -276M | -85M | 33M | -9M |
| EBITDA | -260M | -264M | -76M | 52M | -6M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -96.87 | -265.79 | 1.0 |
| Next quarter | -84.07 | 10.94 | 4.0 |
| Current year | -98.26 | -150.39 | 1.0 |
| Next year | 1804.69 | 169.11 | 10 |
| Weighted average score | 4.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -67.64 | -21.69 | -15.99 | 46.06 | 3.3 |
| Y/Y | -99.46 | -110.9 | -108.28 | 89.08 | 3.3 |
| 3y average | 437.07 | 62.14 | 62.84 | 39.97 | 10 |
| 5y average | 504.55 | 41.67 | 47.87 | 15.27 | 9.8 |
| Weighted average score | 6.6 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |